FindTrial
Sign In

RMC-4630

DRUG5 trials

Sponsors

Revolution Medicines, Inc., Amgen, The Netherlands Cancer Institute

Conditions

Advanced Solid TumorsColorectal CancerKRAS Mutation-Related TumorsKirsten Rat Sarcoma (KRAS) pG12C MutationNon-Small Cell Lung CancerNon-small Cell Lung CancerPancreatic CancerSolid Tumor

Phase 1

Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
NCT03634982
Revolution Medicines, Inc.Solid Tumors
Start: 2018-09-28End: 2023-05-31Updated: 2022-09-01
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
CompletedNCT03989115
Revolution Medicines, Inc.Solid Tumor
Start: 2019-07-02End: 2022-02-08Updated: 2023-06-26
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Active, not recruitingNCT04185883
AmgenAdvanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
Start: 2019-12-17End: 2027-12-05Updated: 2025-10-22
Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers
TerminatedNCT04916236
The Netherlands Cancer InstituteColorectal Cancer, KRAS Mutation-Related Tumors, Non-small Cell Lung Cancer +1
Start: 2022-03-31End: 2024-07-30Updated: 2025-01-24

Phase 2

Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
CompletedNCT05054725
Revolution Medicines, Inc.Non-Small Cell Lung Cancer
Start: 2021-12-30End: 2024-08-29Updated: 2026-01-06

Related Papers

Abstract 2929: Immune and pharmacodynamic effects of sotorasib plus panitumumab in <i>KRAS</i> G12C-mutant colorectal cancer: Paired biopsy results from CodeBreaK 101.
Cancer Research2026-04-03
CRISPR knockout screens reveal JUN as the master mediator of resistance to MAPK inhibition in KRAS-mutant pancreatic cancer.
2026-01-22
Long-term safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated <i>KRAS</i> G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 (phase 1b).
Journal of Clinical Oncology2025-05-284 citations
A phase 3 study of first-line sotorasib, panitumumab, and FOLFIRI versus FOLFIRI with or without bevacizumab-awwb for patients with <i>KRAS</i> G12C–mutated metastatic colorectal cancer (CodeBreaK 301).
Journal of Clinical Oncology2025-01-272 citations
Pooled safety analysis and management of sotorasib-related adverse events in <i>KRAS</i> G12C-mutated advanced non-small cell lung cancer
The Oncologist2025-01-012 citations
Sotorasib plus carboplatin and pemetrexed in <i>KRAS</i> G12C advanced NSCLC: Updated analysis from the international CodeBreaK 101 trial.
Journal of Clinical Oncology2024-06-0115 citations
Sotorasib plus panitumumab for pre-treated non-small cell lung cancer with <i>KRAS</i>G12C mutation: A phase 1b study.
Journal of Clinical Oncology2024-06-011 citations
A phase 1b study of sotorasib combined with panitumumab as second-line treatment of <i>KRAS</i> G12C<i>-</i>mutated colorectal cancer.
Journal of Clinical Oncology2024-01-203 citations
Sotorasib with panitumumab in chemotherapy-refractory KRAS&lt;sup&gt;G12C&lt;/sup&gt;-mutated colorectal cancer: a phase 1b trial.
2024-01-0465 citations
Sotorasib (Soto) plus panitumumab (Pmab) and FOLFIRI for previously treated <i>KRAS </i>G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 phase 1b safety and efficacy.
Journal of Clinical Oncology2023-06-0118 citations
Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer
Cell Reports Medicine2022-11-0133 citations
A phase 1b study of sotorasib, a specific and irreversible KRAS<sup>G12C </sup>inhibitor, in combination with other anticancer therapies in advanced colorectal cancer (CRC) and other solid tumors (CodeBreaK 101).
Journal of Clinical Oncology2022-01-1914 citations
Abstract LB054: Confirmation of target inhibition and anti-tumor activity of the SHP2 inhibitor RMC-4630 via longitudinal analysis of ctDNA in a phase 1 clinical study
Cancer Research2021-07-014 citations
Trial in progress: A phase 1b study of sotorasib, a specific and irreversible KRAS<sup>G12C</sup> inhibitor, as monotherapy in non-small cell lung cancer (NSCLC) with brain metastasis and in combination with other anticancer therapies in advanced solid tumors (CodeBreaK 101).
Journal of Clinical Oncology2021-05-2010 citations
Trial in progress: A phase Ib study of AMG 510, a specific and irreversible KRAS<sup>G12C</sup> inhibitor, in combination with other anticancer therapies in patients with advanced solid tumors harboring <i>KRAS</i> p.G12C mutation (CodeBreak 101).
Journal of Clinical Oncology2020-05-209 citations